X

logo

Science based.
Heart led. 

Mitokatlyst™, the key ingredient in our first product, Mitokatlyst™-E, is the only clinically tested molecule known to stimulate mitochondrial biogenesis, support ATP production, protect mitochondria from damage and dysfunction, and support optimal mitophagy.*

Structural requirements for Mitokatlyst™ activity are highly specific. Closely related structural analogs not only have no efficacy but can also antagonize the effect of this molecule. The product has an exceptional Safety Profile and works at a precise dose and purity.
cell energy supplement

Our Core Research

  • Pharmacokinetic, partial pharmacodynamic and initial safety analysis of (−)-epicatechin in healthy volunteers.* READ MORE
  • Effects of (−)-epicatechin on molecular modulators of skeletal muscle growth and differentiation.* READ MORE
  • (−)-Epicatechin induces mitochondrial biogenesis and markers of muscle regeneration in adults with Becker muscular dystrophy.* READ MORE
  • Acute effects of an oral supplement of (-)-epicatechin on postprandial fat and carbohydrate metabolism in normal and overweight subjects.* READ MORE
  • (−)-Epicatechin Activation of Endothelial Cell Endothelial Nitric Oxide Synthase, Nitric Oxide, and Related Signaling Pathways.* READ MORE
  • A randomized, placebo-controlled, double-blind study on the effects of (−)-epicatechin on the triglyceride/HDLc ratio and cardiometabolic profile of subjects with hypertriglyceridemia: Unique in vitro effects.* READ MORE

Other Select Research

  • (−)-Epicatechin Activation of Endothelial Cell Endothelial Nitric Oxide Synthase, Nitric Oxide, and Related Signaling Pathways*
    READ PAPER
  • 11-β-hydroxysterols as possible endogenous stimulators of mitochondrial biogenesis as inferred from epicatechin molecular mimicry* READ PAPER

New Clinical Trials

  • Chronic Kidney Disease (CKD)
    Human clinical trial to evaluate the effect of (-)-Epicatechin (Blue Oak Nutraceuticals inc. Mitokatlyst™ – E) on mitochondrial dysfunction, muscle function, muscle mass, and myosteatosis in Chronic Kidney Disease (CKD). Initiated at Karolinska Institutet, Sweden. ClinicalTrials.gov ID – NCT06631820